Recent studies proposed that high expression of BCL2A1, CLEC7A or CD14 predicts Venetoclax sensitivity71 and moreover, combinatorial levels of BCL-2-family members in AML leukemic stem cells determine the response to 5-Azacytidine in combination with Venetoclax treatment72. This evidence concerns the gene CD14 and acute myeloid leukemia.